

Guadalupe Garcia-Tsao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1615197/publications.pdf>

Version: 2024-02-01

137
papers

13,045
citations

46984

47
h-index

24232

110
g-index

222
all docs

222
docs citations

222
times ranked

9459
citing authors

#	ARTICLE	IF	CITATIONS
1	Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. <i>Hepatology</i> , 2017, 65, 310-335.	3.6	1,520
2	Management of Varices and Variceal Hemorrhage in Cirrhosis. <i>New England Journal of Medicine</i> , 2010, 362, 823-832.	13.9	890
3	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. <i>Journal of Hepatology</i> , 2014, 60, 1310-1324.	1.8	685
4	Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , 2015, 62, 968-974.	1.8	571
5	Acute kidney injury in cirrhosis. <i>Hepatology</i> , 2008, 48, 2064-2077.	3.6	550
6	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. <i>Nature</i> , 2019, 575, 505-511.	13.7	493
7	Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. <i>Hepatology</i> , 2014, 60, 250-256.	3.6	456
8	Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. <i>Hepatology</i> , 2010, 51, 1445-1449.	3.6	436
9	Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. <i>Gastroenterology</i> , 2001, 120, 726-748.	0.6	416
10	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , 2015, 64, 531-537.	6.1	405
11	Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. <i>Hepatology</i> , 2016, 63, 566-573.	3.6	336
12	Intestinal fungi contribute to development of alcoholic liver disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 2829-2841.	3.9	336
13	Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021, 74, 1014-1048.	3.6	311
14	Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021, 73, 366-413.	3.6	295
15	News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. <i>Journal of Hepatology</i> , 2019, 71, 811-822.	1.8	272
16	Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. <i>Journal of Hepatology</i> , 2016, 64, 717-735.	1.8	243
17	Update to the Society of Radiologists in Ultrasound Liver Elastography Consensus Statement. <i>Radiology</i> , 2020, 296, 263-274.	3.6	205
18	Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. <i>Hepatology</i> , 1991, 13, 902-912.	3.6	197

#	ARTICLE	IF	CITATIONS
19	NACSELD acute-to-chronic liver failure (NACSELD-to-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. <i>Hepatology</i> , 2018, 67, 2367-2374.	3.6	197
20	The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. <i>Hepatology</i> , 2016, 64, 200-208.	3.6	189
21	Gut microflora in the pathogenesis of the complications of cirrhosis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 353-372.	1.0	181
22	Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. <i>Gut</i> , 2021, 70, 531-536.	6.1	178
23	Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis. <i>Gastroenterology</i> , 2016, 150, 430-440.e1.	0.6	159
24	Antibiotic prophylaxis in cirrhosis: Good and bad. <i>Hepatology</i> , 2016, 63, 2019-2031.	3.6	158
25	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 71, 522-538.	3.6	151
26	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 396-405.	1.8	144
27	Bacterial translocation in acute and chronic portal hypertension. <i>Hepatology</i> , 1993, 17, 1081-1085.	3.6	142
28	ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. <i>American Journal of Gastroenterology</i> , 2020, 115, 18-40.	0.2	126
29	Distal splenorenal vs. portal-systemic shunts after hemorrhage from varices: A randomized controlled trial. <i>Hepatology</i> , 1988, 8, 1475-1481.	3.6	110
30	Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. <i>Journal of Hepatology</i> , 2018, 68, 949-958.	1.8	108
31	Long-term Use of Antibiotics and Proton Pump Inhibitors Predict Development of Infections in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 753-759.e2.	2.4	105
32	Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 565-574.e4.	2.4	105
33	Current knowledge and management of portal vein thrombosis in cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 442-453.	1.8	93
34	Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. <i>Hepatology</i> , 2017, 66, 1219-1231.	3.6	80
35	Urinary Biomarkers and Progression of AKI in Patients with Cirrhosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1857-1867.	2.2	79
36	Portal Hypertension. <i>Clinics in Liver Disease</i> , 2019, 23, 573-587.	1.0	78

#	ARTICLE	IF	CITATIONS
37	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 313-327.e6.	2.4	74
38	Intestinal Virome in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 72, 2182-2196.	3.6	74
39	Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2109-2117.	2.4	64
40	Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis. <i>Digestive Diseases</i> , 2016, 34, 382-386.	0.8	62
41	Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo- and Hypercoagulable Features. <i>Hepatology</i> , 2020, 72, 1327-1340.	3.6	60
42	Classification of Cirrhosis: The Clinical Use of HVPG Measurements. <i>Disease Markers</i> , 2011, 31, 121-128.	0.6	59
43	High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of end-stage liver disease. <i>Liver Transplantation</i> , 2015, 21, 881-888.	1.3	59
44	Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis. <i>Liver International</i> , 2018, 38, 1437-1441.	1.9	56
45	Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double-blind randomized echo-doppler study. <i>Hepatology</i> , 1995, 21, 134-139.	3.6	55
46	Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. <i>Liver Transplantation</i> , 2019, 25, 870-880.	1.3	55
47	Spontaneous bacterial peritonitis. <i>Gastroenterology Clinics of North America</i> , 1992, 21, 257-75.	1.0	49
48	Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 78-85.	1.9	47
49	Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. <i>Hepatology</i> , 2019, 69, 1287-1299.	3.6	45
50	Evaluation and Management of Esophageal and Gastric Varices in Patients with Cirrhosis. <i>Clinics in Liver Disease</i> , 2020, 24, 335-350.	1.0	42
51	Targets to improve quality of care for patients with hepatic encephalopathy: data from a multicentre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1518-1527.	1.9	40
52	Bacterial Infections in Cirrhosis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2004, 18, 405-406.	1.8	38
53	Screening and Surveillance of Varices in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 26-29.	2.4	36
54	Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters. <i>Gut</i> , 2016, 65, 1393-1394.	6.1	35

#	ARTICLE	IF	CITATIONS
55	Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure-Related Bleeding in Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2021, 5, 272-282.	2.0	35
56	Liver and Spleen Stiffness Measurements by Point Shear Wave Elastography via Acoustic Radiation Force Impulse. <i>Journal of Ultrasound in Medicine</i> , 2016, 35, 2373-2380.	0.8	34
57	Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes. <i>Hepatology</i> , 2020, 72, 1880-1882.	3.6	30
58	Beta blockers in cirrhosis: The window re-opens. <i>Journal of Hepatology</i> , 2016, 64, 532-534.	1.8	29
59	The diagnostic and predictive value of ascites nitric oxide levels in patients with spontaneous bacterial peritonitis. <i>Hepatology</i> , 1998, 28, 17-21.	3.6	28
60	Significant Liver Injury During Hospitalization for COVID-19 Is Not Associated With Liver Insufficiency or Death. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2182-2191.e7.	2.4	28
61	Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. <i>Hepatology</i> , 1991, 13, 902-912.	3.6	26
62	The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2006, 3, 380-389.	1.7	25
63	Early Trends in Cystatin C and Outcomes in Patients with Cirrhosis and Acute Kidney Injury. <i>International Journal of Nephrology</i> , 2014, 2014, 1-8.	0.7	25
64	A cut-off serum creatinine value of 1.5 mg/dl for AKI "To be or not to be. <i>Journal of Hepatology</i> , 2015, 62, 741-743.	1.8	25
65	The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. <i>Hepatology</i> , 1999, 30, 602-605.	3.6	24
66	Portal hypertension. <i>Current Opinion in Gastroenterology</i> , 2005, 21, 313-322.	1.0	24
67	Novel prevention strategies for bacterial infections in cirrhosis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 689-701.	0.9	21
68	Current Management Strategies for Acute Esophageal Variceal Hemorrhage. <i>Current Hepatitis Reports</i> , 2014, 13, 35-42.	0.3	20
69	Management of acute variceal hemorrhage. <i>F1000Research</i> , 2019, 8, 966.	0.8	20
70	Nonselective Beta-Blockers in Compensated Cirrhosis: Preventing Variceal Hemorrhage or Preventing Decompensation?. <i>Gastroenterology</i> , 2021, 161, 770-773.	0.6	20
71	Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , 2017, 62, 768-776.	1.1	19
72	Model for end-stage liver disease (MELD) exception for hereditary hemorrhagic telangiectasia. <i>Liver Transplantation</i> , 2006, 12, S108-S109.	1.3	18

#	ARTICLE	IF	CITATIONS
73	Transjugular Intrahepatic Portosystemic Shunt in the Management of Refractory Ascites. <i>Seminars in Interventional Radiology</i> , 2005, 22, 278-286.	0.3	17
74	Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. <i>Hepatology</i> , 2020, 72, 1819-1837.	3.6	17
75	Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2571-2579.	1.1	17
76	Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2021, 53, 879-888.	0.4	17
77	Cirrhosis Regression and Subclassification. <i>Surgical Pathology Clinics</i> , 2013, 6, 295-309.	0.7	15
78	Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3612-3618.	1.1	15
79	The Role of Medical Therapy for Variceal Bleeding. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2015, 25, 479-490.	0.6	14
80	Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1661-1669.e2.	2.4	14
81	The Child-Turcotte Classification: From Gestalt to Sophisticated Statistics and Back. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3102-3104.	1.1	13
82	Regression of HCV cirrhosis: Time will tell. <i>Hepatology</i> , 2018, 67, 1651-1653.	3.6	13
83	Simple Clinical Tools to Predict Decompensation in Patients With Compensated Cirrhosis: An Unmet Need. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2179-2181.	2.4	13
84	The interpretation of hepatic venous pressure gradient tracings – excellent interobserver agreement unrelated to experience. <i>Liver International</i> , 2016, 36, 1160-1166.	1.9	12
85	Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Tj ETQq1 1 0.784314 rgBT /Overlock 10 2019, 45, 793-801.	1.5	12
86	Preventing the Development of Varices in Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, S300-S304.	1.1	11
87	The Design of Clinical Trials in Portal Hypertension. <i>Seminars in Liver Disease</i> , 2017, 37, 073-084.	1.8	11
88	Long-term albumin in cirrhosis: is it the ANSWER?. <i>Lancet</i> , The, 2018, 391, 2391-2392.	6.3	11
89	Portal hypertension. <i>Current Opinion in Gastroenterology</i> , 2002, 18, 351-359.	1.0	9
90	Management of Acute Variceal Hemorrhage as a Model of Individualized Care for Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 24-26.	2.4	9

#	ARTICLE	IF	CITATIONS
91	Bacterial translocation in acute and chronic portal hypertension. <i>Hepatology</i> , 1993, 17, 1081-1085.	3.6	9
92	Variation in Treatment Priorities for Chronic Hepatitis C: A Latent Class Analysis. <i>Patient</i> , 2016, 9, 241-249.	1.1	8
93	Variceal Hemorrhage in a Patient With Hepatitis C Virus Cirrhosis in Whom Liver Synthetic Function had Normalized After Viral Elimination. <i>Hepatology</i> , 2016, 63, 1733-1735.	3.6	8
94	Liver Capsule: Portal Hypertension and Varices: Pathogenesis, Stages, and Management. <i>Hepatology</i> , 2017, 65, 1038-1038.	3.6	8
95	Hypervolemic hyponatremia: Clinical significance and management. <i>Clinical Liver Disease</i> , 2013, 2, 109-112.	1.0	7
96	Idiopathic noncirrhotic portal hypertension: What is it?. <i>Clinical Liver Disease</i> , 2015, 5, 120-122.	1.0	7
97	Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 565-572.e5.	2.4	7
98	<scp>SGLT2</scp> inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. <i>Journal of Diabetes</i> , 2021, 13, 265-269.	0.8	7
99	Can We Rely on Changes in HVPG in Patients with Cirrhosis?. <i>Hepatology</i> , 2021, 74, 2945-2947.	3.6	7
100	Admission Serum Metabolites and Thyroxine Predict Advanced Hepatic Encephalopathy in a Multicenter Inpatient Cirrhosis Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1031-1040.e3.	2.4	7
101	Management of varices and variceal hemorrhage in liver cirrhosis: a recent update. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211017.	1.4	7
102	Terlipressin and Intravenous Albumin in Advanced Cirrhosis – Friend and Foe. <i>New England Journal of Medicine</i> , 2021, 384, 869-871.	13.9	6
103	Empowering women: Perspective from a hepatologist. <i>Hepatology</i> , 2016, 64, 1831-1833.	3.6	5
104	Some Answers and More Questions About Portal Vein Thrombosis in Patients With Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2432-2434.	2.4	5
105	Nonalcoholic Steatohepatitis – Opportunities and Challenges. <i>New England Journal of Medicine</i> , 2021, 385, 1615-1617.	13.9	5
106	Prognostic Factors in Compensated and Decompensated Cirrhosis. <i>Current Hepatology Reports</i> , 2014, 13, 171-179.	0.4	4
107	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol-Associated Hepatitis. <i>Liver Transplantation</i> , 2021, 27, 1382-1391.	1.3	4
108	Changes in Ascitic Fluid Polymorphonuclear Cell Count After Antibiotics Are Associated With Mortality in Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1201-e1204.	2.4	4

#	ARTICLE	IF	CITATIONS
109	Reply:. Hepatology, 2017, 66, 302-303.	3.6	2
110	Reply to: "œlt takes two "œeyes"to see in depth" Journal of Hepatology, 2019, 70, 791-793.	1.8	2
111	Reply to: "œLack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis" Journal of Hepatology, 2020, 72, 582-583.	1.8	2
112	Thick Fibrous Septa on Liver Biopsy Specimens Predict the Development of Decompensation in Patients With Compensated Cirrhosis. American Journal of Clinical Pathology, 2021, 156, 802-809.	0.4	2
113	Prognosis of hospitalized patients with cirrhosis and acute kidney disease. Liver International, 2022, , .	1.9	2
114	Portal pressure reductions induced by nonselective beta"œblockers improve outcomes and decrease mortality in patients with cirrhosis with and without ascites. Clinical Liver Disease, 2022, 20, 1-4.	1.0	2
115	Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites. GastroHep, 2022, 2022, 1-8.	0.3	2
116	Portal Hypertension: From the Patient to the Molecule and Back. Journal of Clinical Gastroenterology, 2007, 41, S243-S244.	1.1	1
117	Response to Mancuso et al.. American Journal of Gastroenterology, 2020, 115, 953-953.	0.2	1
118	Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!. Transplant International, 2021, 34, 1325-1327.	0.8	1
119	Reply to "œAcute kidney injury in patients with decompensated cirrhosis" Digestive and Liver Disease, 2021, 53, 1217-1218.	0.4	1
120	Cirrhotic ascites: pathogenesis and management. The Gastroenterologist, 1995, 3, 41-54.	0.6	1
121	Refractory ascites and hepatorenal syndrome. Revista De Gastroenterolog"œa De M"œxico, 2004, 69 Suppl 3, 152-4.	0.4	1
122	Difficult Management Decision. Journal of Clinical Gastroenterology, 2002, 35, S143-S146.	1.1	0
123	Approach to the Patient with Ascites and Its Complications. , 0, , 442-466.		0
124	Ascites and its Complications. , 0, , 2302-2326.		0
125	Reply. Gastroenterology, 2016, 151, 374.	0.6	0
126	Reply. Hepatology, 2018, 68, 791-791.	3.6	0

#	ARTICLE	IF	CITATIONS
127	Reply:. Hepatology, 2018, 68, 2046-2048.	3.6	0
128	Author response to Letter to the Editor "Postparacentesis hemoperitoneum" time to become more careful! Liver International, 2018, 38, 1698-1699.	1.9	0
129	Reply to: "Relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis" Journal of Hepatology, 2018, 69, 748-749.	1.8	0
130	Reply. Liver Transplantation, 2019, 25, 1586-1587.	1.3	0
131	Future Pharmacological Therapies of Portal Hypertension. Current Hepatology Reports, 2019, 18, 36-48.	0.4	0
132	Reply to Risk Stratification in Acute Variceal Bleeding: Child-Pugh Versus Model for End-stage Liver Disease. Journal of Clinical Gastroenterology, 2019, 53, 314-315.	1.1	0
133	Author response to Letter to the Editor: "Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient"™. Liver International, 2020, 40, 990-991.	1.9	0
134	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
135	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 2219.	2.4	0
136	Approach to the Patient with Ascites and Its Complications. , 0, , 447-458.		0
137	Approach to the Patient with Ascites and its Complications. , 0, , 103-113.		0